Rossari Biotech (ROSSARI) Stock Overview
Manufactures and sells specialty chemicals in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ROSSARI from our risk checks.
ROSSARI Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rossari Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹446.15 |
| 52 Week High | ₹690.30 |
| 52 Week Low | ₹375.00 |
| Beta | 0.55 |
| 1 Month Change | -10.30% |
| 3 Month Change | -11.47% |
| 1 Year Change | -28.96% |
| 3 Year Change | -46.12% |
| 5 Year Change | -69.85% |
| Change since IPO | -39.84% |
Recent News & Updates
Narrative Update • Jun 30
ROSSARI: New R&D Relocation Will Support Stronger Long-Term Prospects
Analysts have reduced their fair value estimate for Rossari Biotech from ₹813 to ₹637. This change reflects an updated view that combines a slightly lower discount rate and higher projected revenue growth with expectations of a lower profit margin and a reduced future P/E multiple.
Narrative Update • Jun 16
ROSSARI: Navi Mumbai R And D Shift Will Drive Future Upside
Analysts have kept Rossari Biotech's fair value estimate steady at ₹601.75, with only minor adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially change their overall valuation view. What's in the News Board meeting scheduled for May 27, 2026, at 16:00 IST to consider the re appointment of Ms. Esha Padmanabhan Achan as a Non Executive Independent Director and the grant of options under the Rossari Employee Stock Option Plan 2019.Narrative Update • Jun 01
ROSSARI: New Navi Mumbai R And D Move Will Support Future Upside
Analysts have maintained their fair value estimate for Rossari Biotech at ₹601.75, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, resulting in an unchanged price target. What's in the News A board meeting is scheduled for May 27, 2026 at 16:00 IST to consider the reappointment of Ms. Esha Padmanabhan Achan as a non-executive independent director and to evaluate the grant of options under the Rossari Employee Stock Option Plan 2019.Recent updates
Narrative Update • Jun 30
ROSSARI: New R&D Relocation Will Support Stronger Long-Term Prospects
Analysts have reduced their fair value estimate for Rossari Biotech from ₹813 to ₹637. This change reflects an updated view that combines a slightly lower discount rate and higher projected revenue growth with expectations of a lower profit margin and a reduced future P/E multiple.Narrative Update • Jun 16
ROSSARI: Navi Mumbai R And D Shift Will Drive Future Upside
Analysts have kept Rossari Biotech's fair value estimate steady at ₹601.75, with only minor adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially change their overall valuation view. What's in the News Board meeting scheduled for May 27, 2026, at 16:00 IST to consider the re appointment of Ms. Esha Padmanabhan Achan as a Non Executive Independent Director and the grant of options under the Rossari Employee Stock Option Plan 2019.Narrative Update • Jun 01
ROSSARI: New Navi Mumbai R And D Move Will Support Future Upside
Analysts have maintained their fair value estimate for Rossari Biotech at ₹601.75, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, resulting in an unchanged price target. What's in the News A board meeting is scheduled for May 27, 2026 at 16:00 IST to consider the reappointment of Ms. Esha Padmanabhan Achan as a non-executive independent director and to evaluate the grant of options under the Rossari Employee Stock Option Plan 2019.Narrative Update • May 14
ROSSARI: New R&D Consolidation And Board Decisions Will Drive Future Upside
Analysts now set a revised price target for Rossari Biotech at ₹601.75, down from ₹635.50, reflecting slightly softer assumptions around revenue growth, profit margins, and future P/E multiples. What's in the News Rossari Biotech has set up a new Research and Development Facility at Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai 400 710.Analysis Article • May 04
Rossari Biotech's (NSE:ROSSARI) Profits Appear To Have Quality Issues
Rossari Biotech Limited's ( NSE:ROSSARI ) stock didn't jump after it announced some healthy earnings. We did some...Narrative Update • Apr 25
ROSSARI: Upcoming Board Meeting And Dividend Decision Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.5, with only small technical tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, so the headline price target remains unchanged. What's in the News Board meeting scheduled for April 27, 2026, to review and approve audited standalone and consolidated financial statements for the quarter and financial year ended March 31, 2026 (company filing).Narrative Update • Apr 09
ROSSARI: Greenfield Expansion And Subsidiary Restructuring Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.50, citing only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions rather than any major shift in the core outlook. What's in the News A board meeting is scheduled on January 17, 2026 at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative Update • Mar 26
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have maintained the fair value estimate for Rossari Biotech at ₹635.5, making only minor technical adjustments to assumptions such as the discount rate, revenue growth, profit margin, and future P/E, which result in an essentially unchanged price target view. What's in the News A board meeting is scheduled for January 17, 2026, at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative Update • Mar 08
ROSSARI: Greenfield Expansion And Subsidiary Buildout Will Support Future Upside
Analysts have maintained Rossari Biotech's fair value estimate at ₹635.50, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E to reflect updated modelling assumptions rather than a change in conviction. What's in the News A board meeting is scheduled on Jan 17, 2026 at 12:30 Indian Standard Time to consider unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Narrative Update • Feb 22
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹635.5, with the unchanged price target reflecting only marginal tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Board meeting scheduled for January 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider several key corporate actions, including new projects and asset changes (company filing).Narrative Update • Feb 05
ROSSARI: Greenfield Expansion And Subsidiary Reshaping Will Support Future Upside Potential
Analysts have trimmed their fair value estimate for Rossari Biotech slightly from ₹637.33 to ₹635.50, reflecting updated assumptions around discount rate, profit margin and future P/E, while keeping revenue growth expectations broadly aligned with prior views. What's in the News Board meeting scheduled on Jan 17, 2026 at 12:30 IST to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to consider several corporate actions (company filing).Narrative Update • Jan 22
ROSSARI: International Capacity Expansion Plans Will Drive Future Upside Potential
Analysts have revised their price target on Rossari Biotech lower from ₹795.75 to about ₹637.33, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. What's in the News A board meeting is scheduled on Jan 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Analysis Article • Jan 22
Analysts Have Lowered Expectations For Rossari Biotech Limited (NSE:ROSSARI) After Its Latest Results
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...Narrative Update • Jan 08
ROSSARI: International Capacity Expansions Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹795.75, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E to better reflect current expectations. What's in the News A board meeting is scheduled on December 18, 2025 at 10:30 a.m. Indian Standard Time to consider and approve the incorporation of a wholly owned subsidiary in the Republic of Singapore (company filing).Narrative Update • Dec 21
ROSSARI: Planned Singapore Subsidiary Will Drive Future International Expansion Upside
Analysts have reaffirmed their price target on Rossari Biotech at ₹795.75 per share, with only marginal tweaks to underlying assumptions such as discount rate, long term revenue growth, profit margin, and future P E multiple, reflecting a largely unchanged outlook on the company’s earnings trajectory and risk profile. What's in the News Board to meet on December 18, 2025, to consider incorporating a wholly owned subsidiary in the Republic of Singapore (Board Meeting) Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility, taking total installed capacity to 1,52,500 MTPA (Business Expansions) Commissioned 15,000 MTPA ethoxylation capacity at Unitop in Phase 1 of a 30,000 MTPA plan, with Phase 2 expected by the third quarter of fiscal 2026 (Business Expansions) Board approved an investment of up to USD 8 million in Rossari International Limited Company in Saudi Arabia to evaluate and assess expansion plans in international markets (Business Expansions) Board meeting scheduled on October 15, 2025, to approve unaudited financial results for the quarter and half year ended September 30, 2025 (Board Meeting) Valuation Changes The consensus analyst price target remains unchanged at ₹795.75 per share, indicating a stable fair value assessment.Narrative Update • Dec 06
ROSSARI: Capacity Expansion And Saudi Subsidiary Investment Will Drive Future Upside
Narrative Update on Rossari Biotech Analysts have maintained their price target for Rossari Biotech at ₹795.75, citing largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. Taken together, these factors suggest limited change in the company’s fundamental outlook.Narrative Update • Nov 22
ROSSARI: Additional Capacity Expansions Will Unlock Global Opportunities Ahead
Narrative Update on Rossari Biotech Analysts have maintained their fair value estimate for Rossari Biotech at ₹795.75, citing minimal changes in key financial assumptions and continued confidence in the company’s outlook. What's in the News Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility during the quarter, bringing total installed capacity to 1,52,500 MTPA.Narrative Update • Nov 04
ROSSARI: New Expansion Projects Will Drive Global Market Penetration
Narrative Update on Rossari Biotech: Analyst Price Target Revision Analysts have revised Rossari Biotech’s fair value estimate downward from ₹826.67 to ₹795.75, citing slightly lower expectations for revenue growth and profit margins. What's in the News The company commissioned an additional 20,000 MTPA capacity at its Dahej facility, bringing total installed capacity to 1,52,500 MTPA (Key Developments).Analysis Article • Oct 28
We Think That There Are More Issues For Rossari Biotech (NSE:ROSSARI) Than Just Sluggish Earnings
Rossari Biotech Limited's ( NSE:ROSSARI ) recent weak earnings report didn't cause a big stock movement. Our analysis...Analysis Article • Jun 24
Here's Why Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights Rossari Biotech will host its Annual General Meeting on 30th of June Total pay for CEO Sunil Chari...
New Narrative • Feb 10
Eco-friendly Solutions And New Capacities Will Strengthen Future Prospects
Strategic investments in capacity expansion and innovation in eco-friendly solutions are expected to drive revenue growth in domestic and international markets.Analysis Article • Aug 17
Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All
Key Insights Rossari Biotech's Annual General Meeting to take place on 23rd of August Salary of ₹12.1m is part of CEO...Analysis Article • Jun 14
Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • May 07
Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals
Investors were disappointed with Rossari Biotech Limited's ( NSE:ROSSARI ) earnings, despite the strong profit numbers...Analysis Article • May 03
Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report
Last week, you might have seen that Rossari Biotech Limited ( NSE:ROSSARI ) released its full-year result to the...Analysis Article • Feb 10
One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically
The analyst covering Rossari Biotech Limited ( NSE:ROSSARI ) delivered a dose of negativity to shareholders today, by...Analysis Article • Sep 23
Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...Analysis Article • Apr 06
Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Feb 19
Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues
Rossari Biotech Limited ( NSE:ROSSARI ) shareholders will have a reason to smile today, with the analysts making...Analysis Article • Feb 17
Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...Analysis Article • Feb 10
I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Analysis Article • Nov 24
Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Oct 12
With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Shareholder Returns
| ROSSARI | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | -3.1% | -1.2% | -1.4% |
| 1Y | -29.0% | -1.6% | -1.2% |
Return vs Industry: ROSSARI underperformed the Indian Chemicals industry which returned -1.6% over the past year.
Return vs Market: ROSSARI underperformed the Indian Market which returned -1.2% over the past year.
Price Volatility
| ROSSARI volatility | |
|---|---|
| ROSSARI Average Weekly Movement | 4.2% |
| Chemicals Industry Average Movement | 5.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Stable Share Price: ROSSARI has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ROSSARI's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 585 | Sunil Chari | www.rossari.com |
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers home, personal care, and performance chemicals products, such as soaps and detergents; oil and gas division; inks; paints and coatings; ceramics and tiles; pulp and paper; cement; water treatment; performance additives; cleaning, hygiene, and disinfection; surfactants; and textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions. The company also provides pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, and creams; and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names.
Rossari Biotech Limited Fundamentals Summary
| ROSSARI fundamental statistics | |
|---|---|
| Market cap | ₹24.71b |
| Earnings (TTM) | ₹1.51b |
| Revenue (TTM) | ₹25.50b |
16.4x
P/E Ratio1.0x
P/S RatioIs ROSSARI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROSSARI income statement (TTM) | |
|---|---|
| Revenue | ₹25.50b |
| Cost of Revenue | ₹17.97b |
| Gross Profit | ₹7.53b |
| Other Expenses | ₹6.02b |
| Earnings | ₹1.51b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 27.21 |
| Gross Margin | 29.53% |
| Net Profit Margin | 5.91% |
| Debt/Equity Ratio | 32.7% |
How did ROSSARI perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield2%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/12 21:22 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rossari Biotech Limited is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Nitesh Dhoot | Anand Rathi Shares and Stock Brokers Limited |
| Abhishek Navalgund | Centrum Broking Limited |